Yezan Munther Haddadin is Director at Outlook Therapeutics, Inc. (OTLK). They have made 7 open-market trades across 1 company since 2020, most recently 2026-06-02.
CIK 0001718004
7 open-market purchases totalling $144K since 2020, never a sale. Across 7 scored buys the stock is up 10.8% at ninety days, and 7.2 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| OTLK | 66,167 | $32K |
Shares reported on the most recent Form 4, priced at the 2026-06-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 57% | 71% | 43% |
| Avg Move | +7.3% | +33.5% | +10.8% |
| Alpha | +6.6% | +31.5% | +7.2% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OTLK | BUY | 2026-06-02 | 2026-06-03 | $0.83 | $24K | +46.9% | +77.5% | -22.3% |
| OTLK | BUY | 2026-05-26 | 2026-05-27 | $0.44 | $15K | +12.7% | +166.7% | -0.6% |
| OTLK | BUY | 2024-03-28 | 2024-03-29 | $11.82 | $22K | -27.3% | -26.4% | -39.2% |
| OTLK | BUY | 2022-10-06 | 2022-10-11 | $1.29 | $43K | -4.8% | -16.1% | -15.3% |
| OTLK | BUY | 2021-12-02 | 2021-12-02 | $1.39 | $14K | -2.1% | +2.8% | +19.7% |
| OTLK | BUY | 2021-04-19 | 2021-04-20 | $1.82 | $18K | +25.3% | +24.2% | +23.7% |
| OTLK | BUY | 2020-09-22 | 2020-09-22 | $0.72 | $7K | +0.1% | +5.8% | +110.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.